Evidence map›Paper›PMID 33802888›Full record

ArticleMolecules (Basel, Switzerland)2021

Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.

Minjin Yoo, Tae Hyun Park, Miyoun Yoo, Yeongrin Kim, Joo-Youn Lee, Kyu Myung Lee, Seong Eon Ryu, Byung Il Lee, Kwan-Young Jung, Chi Hoon Park

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Bromodomain inhibitors and therapeutic applications.Current opinion in chemical biology · 2023
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Minjin YooDepartment of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Korea.
Tae Hyun ParkResearch Institute, National Cancer Center, Goyang-si, Gyeonggi 10408, Korea.ORCID 0000-0001-8059-8273
Miyoun YooTherapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.
Yeongrin KimDepartment of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Korea.
Joo-Youn LeeTherapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.
Kyu Myung LeeTherapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.ORCID 0000-0001-9525-8239
Seong Eon RyuDepartment of Bioengineering, Hanyang University, Seoul 04763, Korea.
Byung Il LeeResearch Institute, National Cancer Center, Goyang-si, Gyeonggi 10408, Korea.ORCID 0000-0003-1270-8439
Kwan-Young JungDepartment of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Korea.
Chi Hoon ParkDepartment of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Korea.

Funding

Korea Research Institute of Chemical Technology BSF20-402National Research Foundation of Korea NRF-2018R1C1B6002932
6 · The paper itself

Abstract

Epigenetic regulation is known to play a key role in progression of anti-cancer therapeutics. Lysine acetylation is an important mechanism in controlling gene expression. There has been increasing interest in bromodomain owing to its ability to modulate transcription of various genes as an epigenetic 'reader.' Herein, we report the design, synthesis, and X-ray studies of novel aristoyagonine (benzo[6,7]oxepino[4,3,2-

Indexed as

AcetylationBinding SitesBromodomain Containing ProteinsCell Cycle ProteinsCell LineCrystallography, X-RayEnzyme InhibitorsHumansInhibitory Concentration 50IsoquinolinesLysineProtein BindingProtein DomainsStructure-Activity RelationshipTranscription FactorsaristoyagonineBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsEnzyme InhibitorsIsoquinolinesLysineTranscription FactorsaristoyagonineBrd4crystal structureepigeneticSAR

Identifiers

PMID33802888
PMCPMC8002823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.